Abstract:The F-box protein 22 (FBXO22), an F-box E3 ligase, has been identified to be critically involved in carcinogenesis. However, a systematic assessment of the role of FBXO22 across human cancers is lacking. Here, we performed a pan-cancer analysis to explore the role of FBXO22 in 33 cancer types using multiomic data from The Cancer Genome Atlas (TCGA). First, we found that high FBXO22 expression in multiple cancers was closely associated with poor overall survival and relapse-free survival. Next, we identified ten proteins that interact with FBXO22 and 13 of its target substrates using the STRING database and a literature search to explore the regulatory role of FBXO22 in tumorigenesis. Genes encoding these proteins were found to be significantly enriched in cell cycle negative regulation and ubiquitination pathways. This was confirmed in nonsmall cell lung cancer A549 cells, where FBXO22 overexpression enhanced cyclin-dependent kinase 4 (CDK4) protein levels and promoted cell proliferation. Similarly, overexpression or interference of FBXO22 changed the protein level of one of its substrates, PTEN. Additionally, we found that FBXO22 mutations were accompanied by altered substrate expression, especially in uterine corpus endometrial carcinoma and lung adenocarcinoma; endometrial carcinoma patients with FBXO22 genetic alterations also had better overall and relapse-free survival. Notably, FBXO22 methylation levels were also decreased in most tumors, and hypomethylation of FBXO22 was associated with poor overall survival, relapse-free interval, and progression-free interval in pancreatic adenocarcinoma. Finally, we analyzed the correlation between the abundance of tumor infiltrating lymphocytes (TILs) and FBXO22 expression, copy number variation, and methylation. Multiple algorithms revealed that high FBXO22 expression was associated with lower TIL levels, especially in lung adenocarcinoma, lung squamous cell carcinoma, and sarcoma. Taken together, our findings demonstrate that FBXO22 degrades tumor suppressor genes by ubiquitination and inhibits the cell cycle to promote nonsmall cell lung cancer progression. Our study also provides a relatively comprehensive understanding of the oncogenic role of FBXO22 in different tumors.

The Β-Trcp-fbxw2-skp2 Axis Regulates Lung Cancer Cell Growth with FBXW2 Acting As a Tumour Suppressor.

FBXW2 Suppresses Proliferation and Invasion of Lung Cancer Cells by Targeting SKP2 and Β-Catenin.

The Characteristics and Roles of Β‐trcp1/2 in Carcinogenesis

Functional Characterization of FBXL7 As a Novel Player in Human Cancers

FBXW2 Suppresses Migration and Invasion of Lung Cancer Cells Via Promoting Β-Catenin Ubiquitylation and Degradation

FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation

FBXO25 Promotes Cell Proliferation, Invasion, and Migration of NSCLC

Pan-Cancer Analyses Reveal Oncogenic Role and Prognostic Value of F-Box Only Protein 22

Clinical significance of FBXW7 loss of function in human cancers

Molecular insights and clinical implications for the tumor suppressor role of SCFFBXW7 E3 ubiquitin ligase

Fbxo22 promotes cervical cancer progression via targeting p57Kip2 for ubiquitination and degradation

FBXO43 Promotes Cell Cycle Progression in Cancer Cells Through Stabilizing SKP2

FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2

FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy

Ubiquitination of NF-κB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance

F-box Protein FBXO31 Modulates Apoptosis and Epithelial-Mesenchymal Transition of Cervical Cancer Via Inactivation of the PI3K/AKT-mediated MDM2/p53 Axis.

FBXW7 in Cancer: What Has Been Unraveled Thus Far?

Pan-cancer analysis of FBXW family with potential implications in prognosis and immune infiltration

FBXO2 promotes the progression of papillary thyroid carcinoma through the p53 pathway

SKP2-mediated FBXO2 proteasomal degradation drives hepatocellular carcinoma progression via stabilizing Hsp47

FBXO28 promotes the malignancy of non-small cell lung cancer through ubiquitination-mediated activation of BRD4